← Leaderboards
Dan M. Granoff
Children'S Hospital &Res Ctr At Oakland
$16,848,708
Attributed
$18,197,713
Total exposure
10
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2005–18$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$18,197,713 · 10
By mechanism
R01$17,431,814 · 5
R21$440,275 · 1
M01$325,624 · 4
Top collaborators
- Peter T. Beernink4 shared
Most similar at Children'S Hospital &Res Ctr At Oakland
Same institution · by research overlap
- David Manh-Tung Vu$1,078,553
- Gregory R Moe$5,802,708
- Deborah Anne Dean$16,812,344
- Donald C Reason$4,483,455
Others in their field
Top investigators on “Neisseria Meningitidis”
- Paul R Cieslak · Public Health Services$9,719,088
- Peter T. Beernink · Children'S Hospital & Res Ctr At Oakland$8,127,751
- Lee Mark Wetzler · Boston Medical Center$5,971,719
- Gregory R Moe · Children'S Hospital &Res Ctr At Oakland$5,802,708
- Magdalene Y So · Oregon Health And Science University$5,696,386
- Peter A. Rice · Univ Of Massachusetts Med Sch Worcester$5,433,391
Research focus
Neisseria MeningitidisAntibody FormationMeningitisVaccinesResponseAntibodiesAntigensBaseProteinsBactericideSerumComplementInfantEngineeringMeningococcal VaccineImmunogenicityMediatingRecombinant ProteinsPrimatesBinding ProteinsComplement Factor HMutantConjugate VaccinesPolysaccharides
Grant awards (38)
The effect of binding of fH to meningococcal fHbp vaccine on antibody protection$557,770
R01 · FY2018 · AI · contact PI
Meningococcal serogroup B vaccine to prevent invasive disease and carriage$641,748
R01 · FY2017 · AI · contact PI
The effect of binding of fH to meningococcal fHbp vaccine on antibody protection$627,269
R01 · FY2017 · AI · contact PI
The effect of binding of fH to meningococcal fHbp vaccine on antibody protection$774,128
R01 · FY2016 · AI · contact PI
Meningococcal serogroup B vaccine to prevent invasive disease and carriage$641,748
R01 · FY2016 · AI · contact PI
The effect of binding of fH to meningococcal fHbp vaccine on antibody protection$738,843
R01 · FY2015 · AI · contact PI
Meningococcal serogroup B vaccine to prevent invasive disease and carriage$641,748
R01 · FY2015 · AI · contact PI
Meningococcal serogroup B vaccine to prevent invasive disease and carriage$672,223
R01 · FY2014 · AI · contact PI
Novel vaccine strategies for prevention of N. meningitidis group B disease$550,570
R01 · FY2013 · AI · contact PI
An engineered meningococcal OMV vaccine for Africa against all capsular groups$442,030
R01 · FY2013 · AI · contact PI
An engineered meningococcal OMV vaccine for Africa against all capsular groups$650,640
R01 · FY2012 · AI · contact PI
Novel vaccine strategies for prevention of N. meningitidis group B disease$631,670
R01 · FY2012 · AI · contact PI
Novel vaccine strategies for prevention of N. meningitidis group B disease$651,283
R01 · FY2011 · AI · contact PI
An engineered meningococcal OMV vaccine for Africa against all capsular groups$477,792
R01 · FY2011 · AI · contact PI
Novel vaccine strategies for prevention of N. meningitidis group B disease$604,832
R01 · FY2010 · AI · contact PI
An engineered meningococcal OMV vaccine for Africa against all capsular groups$481,500
R01 · FY2010 · AI · contact PI
Novel vaccine strategies for prevention of N. meningitidis group B disease$587,866
R01 · FY2009 · AI · contact PI
Novel vaccine approaches for N. meningitidis disease$594,344
R01 · FY2007 · AI · contact PI
Molecular basis meningococcal group A capsular immunity$503,268
R01 · FY2007 · AI · contact PI
Novel vaccine approaches for N. meningitidis disease$600,614
R01 · FY2006 · AI · contact PI
Molecular basis meningococcal group A capsular immunity$506,984
R01 · FY2006 · AI · contact PI
Novel vaccine approaches for N. meningitidis disease$603,651
R01 · FY2005 · AI
Molecular basis meningococcal group A capsular immunity$507,938
R01 · FY2005 · AI
Neisseria meningitidis antigens expressed in infection$240,150
R21 · FY2005 · AI
MEN C$80,878
M01 · FY2005 · RR
MEN B$25,907
M01 · FY2005 · RR
MEN B$220
M01 · FY2005 · RR
Novel vaccine approaches for N. meningitidis disease$602,069
R01 · FY2004 · AI
Molecular basis meningococcal group A capsular immunity$504,141
R01 · FY2004 · AI
Neisseria meningitidis antigens expressed in infection$200,125
R21 · FY2004 · AI
MEN C$183,413
M01 · FY2004 · RR
MEN B$30,347
M01 · FY2004 · RR
MEN A$4,859
M01 · FY2004 · RR
CONSERVED NEISSERIA PROTEINS AS VACCINE CANDIDATES$509,328
R01 · FY2002 · AI
MIMETICS OF CAPSULAR EPITOPES OF NEISSERIA MENINGITIDIS$568,085
R01 · FY2001 · AI
CONSERVED NEISSERIA PROTEINS AS VACCINE CANDIDATES$497,729
R01 · FY2001 · AI
MIMETICS OF CAPSULAR EPITOPES OF NEISSERIA MENINGITIDIS$562,538
R01 · FY2000 · AI
CONSERVED NEISSERIA PROTEINS AS VACCINE CANDIDATES$497,465
R01 · FY2000 · AI